As New York’s premier healthcare network, the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine (WCM) and NewYork-Presbyterian Hospital (NYP) is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine using a personalized approach. The patients‘ enrollment starts at the Institute through an Institutional Review Board-approved clinical trial, then we obtain samples of both their normal and tumor tissue and analyze these samples using genomic sequencing techniques. In our state-of-the-art clinical genomics lab, we also include the integration of Organoids for drug testing. This sequencing strategy enables us to identify specific targets for treatment. The results of our genomic analysis and patients’ medical history are reviewed by a multi-institutional Precision Medicine Tumor Board, which includes experts in medical oncology, pathology, computational biology, genetics, and ethics. The Tumor Board will collaboratively develop a treatment plan tailored to each patient, and EIPM will then share this plan with patients’ clinicians, who then discuss the results with the patient. Our physicians follow up with the patients to see how they are responding to therapy and this information is captured in a clinical database that helps the EIPM team discover and develop therapeutic approaches to benefit many more patients with cancer and other diseases.
Disease Targeting Initiatives
In EIPM, we are changing the face of how we diagnose, treat, and care for patients using a personalized approach and genomic sequencing data. Some of the most serious diseases can be traced in our genome. For these diseases, here in the Englander Institute for Precision Medicine (EIPM), we aim to deliver more effective treatments by identifying and characterizing genomic changes underlying genetic-based ailments. In EIPM we collaborate with clinical departments of WCM and NYP to provide a comprehensive interpretation of patient genomes and act as a permanent resource for our clinicians to make effective use of genomic data to optimize patient care. To this effort, we are channeling our efforts towards developing therapies where genomic data contribute significantly to the clinical result and offer hope for transforming health care.
Cancer Moonshot – Reaching for the stars
People are the heart and soul of our institution. Our faculty and staff — physicians, scientists and administrators based in New York City — strive every day to provide the best patient care and to discover innovative cures and treatments. Learn more about our physicians, the conditions we treat and how our collaborative, patient-centered approach inspires us each day to improve the lives of those we treat.